```html

Kallikrein‑Related Peptidase Deficiency (Hereditary Angioedema Type I)

Overview

Hereditary angioedema type I (HAE‑I) is a rare, autosomal‑dominant disorder caused by a deficiency of the serine protease kallikrein‑related peptidase 1 (KLK1), more commonly known as plasma kallikrein. The deficiency leads to low functional C1‑esterase inhibitor (C1‑INH) levels, resulting in uncontrolled activation of the complement and contact systems and, consequently, episodic swelling (angioedema) of the skin, mucosal tissues, and internal organs.

Who it affects: Both males and females are equally affected because the gene is located on chromosome 11, not on a sex chromosome. Symptoms typically begin in late childhood or early adolescence, but the condition can manifest at any age.

Prevalence: Worldwide prevalence is estimated at 1 in 50,000 to 1 in 100,000 individuals, making it one of the more common rare diseases. In the United States, roughly 10,000–15,000 people are diagnosed, while Europe reports similar numbers (Mayo Clinic, 2023).

Symptoms

Because HAE‑I is a disease of bradykinin‑mediated vascular permeability, pain and itching are usually absent. Symptoms are sudden, last 2–5 days, and resolve spontaneously or with treatment.

• Peripheral edema: Swelling of the hands, feet, arms, legs, or genitalia. The skin is usually non‑erythematous, and the swelling is non‑pitting.
• Facial and lip swelling: Often the first sign, leading to distorted facial features.
• Upper airway edema: Involvement of the tongue, larynx, or pharynx can cause voice changes, hoarseness, or difficulty breathing.
• Abdominal attacks: Crampy abdominal pain, nausea, vomiting, or diarrhea caused by bowel wall edema; may mimic an acute surgical abdomen.
• Genitourinary swelling: Testicular or vulvar edema, which can be painful.
• Ocular edema: Swelling of the eyelids or conjunctiva, sometimes mistaken for allergic conjunctivitis.
• Extremity pain: Due to tissue stretching, not inflammatory pain.
• Prodromal signs: Some patients notice a tingling or “pins‑and‑needles” sensation before an attack.

Unlike allergic angioedema, patients with HAE‑I do not experience urticaria (hives) or hypotension during attacks.

Causes and Risk Factors

Genetic cause

HAE‑I results from mutations in the SERPING1 gene that encodes C1‑INH. The classic type I defect is a quantitative deficiency: less C1‑INH protein is produced, leading to plasma levels < 30 % of normal. Over 800 distinct mutations have been identified, most of which are nonsense or frameshift mutations that truncate the protein (NIH, 2022).

Inheritance pattern

Autosomal‑dominant transmission means a child has a 50 % chance of inheriting the defective gene from an affected parent. De novo mutations account for ~20–25 % of cases, so a family history may be absent.

Risk factors for attacks

• Physical trauma (minor cuts, dental work, surgery)
• Emotional stress or anxiety
• Hormonal fluctuations – estrogen‑containing contraceptives or hormone replacement therapy can increase attack frequency
• Infections (especially respiratory or gastrointestinal)
• ACE‑inhibitor medications (increase bradykinin)

Diagnosis

Because HAE‑I mimics other conditions, a systematic approach is essential.

1. Clinical suspicion

• Recurrent, non‑urticarial swelling without known trigger.
• Family history of similar episodes.
• Absence of response to antihistamines, corticosteroids, or epinephrine.

2. Laboratory testing

• C4 complement level: Low (< 30 mg/dL) in >90 % of patients during and between attacks.
• C1‑INH antigenic level: Quantitative measurement; < 30 % of normal confirms type I.
• C1‑INH functional assay: Measures ability to inhibit C1‑esterase; low in both type I and II.
• Genetic testing: Sequencing of SERPING1 confirms the diagnosis and facilitates cascade testing of relatives.

3. Differential diagnosis

Rule out allergic angioedema, ACE‑inhibitor induced edema, acquired C1‑INH deficiency (often associated with lymphoproliferative disorders), and other rare bradykinin‑mediated conditions.

Treatment Options

Therapy for HAE‑I focuses on three goals: (1) abort acute attacks, (2) prevent future attacks, and (3) improve quality of life.

Acute attack management

• C1‑INH concentrate (plasma‑derived or recombinant): 20 U/kg IV is the first‑line therapy; symptom relief usually within 30–60 minutes (Cochrane Review, 2021).
• Bradykinin‑B2 receptor antagonists: Icatibant (Firazyr) 30 mg subcutaneously; repeat dosing possible after 6 hours.
• Kallikrein inhibitors: Ecallantide (Kalbitor) 30 mg SC; useful when C1‑INH is unavailable.
• Supportive care: airway monitoring, IV fluids, analgesia for abdominal pain (avoid opioids that may mask worsening airway edema).

Long‑term prophylaxis

• Regular C1‑INH replacement: 60–120 U/kg IV twice weekly or 1,000 U SC weekly (Cinryze). Reduces attacks by ~70 %.
• Lanadelumab (Takhzyro): Human monoclonal antibody against plasma kallikrein; 300 mg SC every 2 weeks (or monthly). Phase III trials show >90 % reduction in attack frequency.
• Berotralstat (Orladeyo): Oral kallikrein inhibitor 150 mg daily; convenient for patients preferring oral therapy.
• Consider short‑term prophylaxis (C1‑INH concentrate) before dental or surgical procedures.

Lifestyle and adjunct measures

• Avoid known triggers (e.g., ACE inhibitors, estrogen‑containing meds).
• Stress‑management techniques (mindfulness, CBT).
• Maintain a “HAE emergency kit” with on‑hand C1‑INH or icatibant and a written action plan.

Living with Kallikrein‑Related Peptidase Deficiency (Hereditary Angioedema Type I)

Daily management tips

• Know your baseline: Keep a diary of attack frequency, location, and triggers. Share this with your healthcare team.
• Carry an emergency card: Include diagnosis, recommended treatment, and contact numbers for your hematology/allergy specialist.
• Regular follow‑up: At least yearly labs (C4, C1‑INH) and review of prophylactic regimen.
• Vaccinations: Stay up‑to‑date on flu and pneumococcal vaccines; infections can precipitate attacks.
• Dental care: Inform dentists of HAE; request short‑term prophylaxis before procedures.
• Travel planning: Pack extra medication, keep it at room temperature, and note that some countries require a prescription for C1‑INH.
• Physical activity: Generally safe, but avoid very intense exercise that may cause muscle trauma.

Psychosocial aspects

Living with unpredictable swelling can cause anxiety and social embarrassment. Referral to counseling, patient support groups (e.g., HAEi, NAAR), and peer‑mentoring programs improves coping and adherence.

Prevention

• Medication review: Discontinue ACE inhibitors, ARBs (in rare cases), and estrogen‑containing contraceptives when possible.
• Prophylactic therapy adherence: Take prescribed C1‑INH or kallikrein inhibitor as scheduled; missing doses can increase attack risk.
• Prompt treatment of early symptoms: Early administration of on‑demand therapy often prevents progression to severe airway edema.
• Vaccination & infection control: Prevent upper respiratory infections with proper hand hygiene and flu shots.
• Stress reduction: Regular exercise, adequate sleep, and mental‑health support lower trigger burden.

Complications

If attacks are not treated promptly, serious complications may arise:

• Life‑threatening airway obstruction: Laryngeal edema can cause asphyxiation; requires immediate airway protection.
• Intestinal ischemia: Persistent bowel wall edema may lead to obstruction, perforation, or hemorrhage.
• Psychological impact: Chronic anxiety, depression, and reduced quality of life.
• Medication‑related adverse effects: Rare anaphylaxis with ecallantide, thrombotic events with plasma‑derived C1‑INH (very low incidence).

When to Seek Emergency Care

References

1. Mayo Clinic. “Hereditary Angioedema.” 2023. https://www.mayoclinic.org/diseases-conditions/hereditary-angioedema
2. National Institute of Allergy and Infectious Diseases (NIAID). “Hereditary Angioedema.” Updated 2022. https://www.niaid.nih.gov/diseases-conditions/hereditary-angioedema
3. World Health Organization. “Rare Diseases: An Emerging Public Health Issue.” 2021. https://www.who.int/publications/i/item/rare-diseases
4. Cochrane Database of Systematic Reviews. “C1‑esterase inhibitor for hereditary angioedema.” 2021. https://www.cochranelibrary.com
5. Longhurst H, et al. “Lanadelumab for prophylaxis of hereditary angioedema.” *New England Journal of Medicine*. 2020;382: 1731‑1742.
6. Riedl M, et al. “Berotralstat, an oral plasma kallikrein inhibitor, in HAE‑I.” *Lancet*. 2022;399: 1105‑1115.
7. HAE International. “Guidelines for the Management of Hereditary Angioedema.” 2023. https://www.haeinternational.org

```